Current Issue: December 2025
Feature Article
What Cancer Patients May or May Not Be Surprised to Know About Survivorship
Abstract: The number of US cancer survivors has increased from fewer than 4 million in the 1970s to 18.1 million in 2022, with the increase reflecting […]
Advances in LLM
What Is the Role of Asciminib in Chronic Myeloid Leukemia?
H&O What is the mechanism of action of asciminib? JC Asciminib (Scemblix, Novartis) is a tyrosine kinase inhibitor (TKI) that has a unique mechanism of action […]
Letter From the Editor
Letter From the Editor: Just Say Cure
Given the many difficult discussions we have with patients who have cancer, I find it odd that oncologists still struggle with the word cure. At the […]
Advances in Hematology
The Diagnosis and Treatment of Red Cell Membrane Disorders: Algorithm for the General Hematologist
H&O What is the first step in evaluating a patient with hemolysis? TK The first step is to take a history and conduct a physical examination. […]
Gynecologic Cancer in Focus
Management of Low-Grade Serous Carcinoma of the Ovary
H&O How common is low-grade serous ovarian cancer? RG Low-grade serous ovarian cancer accounts for fewer than 10% of new cases of epithelial ovarian cancer, so […]
Advances in Drug Development
Access to Novel Cancer Drugs in Low- and Middle-Income Countries
H&O What are the biggest barriers preventing patients with cancer in India from accessing novel drugs? AP Accessing novel cancer drugs in India remains a major […]
Supplements:
Ravulizumab–Danicopan Combination Therapy in PNH Management
In the Clinic AB presented to our clinic in 2017, at the age of 70, for a second opinion regarding management of paroxysmal nocturnal hemoglobinuria (PNH) […]